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AbstractThe mineralized matrix of bone makes it difficult to examine specific populations of cells
which are integral to the tissue using traditional molecular methods. For this study we
examined single cell cortical osteoblasts derived from the femurs of C57BL/6J mice.
After isolating single cells from bone, we were able to individually analyze their gene
expression profiles using the quantitative polymerase chain reaction (qPCR). The mice
used for the study were divided into 4 treatment groups, including ovariectomized mice
(OVX) and sham surgical controls (SHAM), treated with or without the anti-resorptive
bisphosphonate drug Alendronate, an effective FDA approved therapeutic for slowing
bone loss in association with osteoporosis. To administer Alendronate, mice were
treated with 100 µg/kg Alendronate weekly via intraperitoneal (IP) injections. After a 16week period post-surgery, mice were euthanized and bone tissue, including spines and
femurs, were preserved for analysis (n= 10 mice per treatment per time point). Single
cell cortical osteoblasts were obtained from preserved femur through serial collagenase
digestion. Osteoblasts cells were collected by selecting for CD31-/CD45-/Alkaline
Phosphatase+ using fluorescence-activated cell sorting (FACS). Over 100 osteoblast
cells per treatment group were analyzed using qPCR for the detection of 96 specific
transcripts. We confirmed the effects of bone loss in the mice due to OVX surgery via
CT scans of the collected spines and femurs at a resolution of 9µm. We identified
unique expression patterns in each treatment subset of osteoblast cells. The single cell
gene expression analysis revealed that the cell populations that were undergoing bone
loss had genetic signatures with distinctive gene expression profiles. Analysis of cells at
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a single cell level may lead to a better understanding of the effects of anti-resorptive
agents on the cell populations found within bone.
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Introduction
Goal of Project:
The main goal of this project is to analyze single cell gene expression profiles in
individual osteoblast cells isolated from the bones of ovariectomized mice treated with
and without Alendronate treatment, and to identify the changes within the osteoblast
expression profiles. The first objective of this experiment is to determine the differences
in gene expression between osteoblasts isolated from ovariectomized versus sham
treated control mice, and then relate this to bone micro-architecture as determined by
micro computerized tomography (umCT). The second objective is to test the differential
gene expression profiles from Alendronate treated OVX mice versus OVX controls.
These results will help demonstrate how estrogen deficiency and the prevention of bone
loss with anti-resoprtives specifically alter the gene expression profiles of primary
cortical osteoblasts at the single cell level.

Background:
Bone remodeling is the process in which bone is continuously replaced by new
tissue, often in response to fractures or micro damage that occur normally in order to
repair damaged bone. It is involved in the maintenance of systemic calcium
homeostasis, replacing damaged bone, and controlling the growth and development of
bone(1). Remodeling occurs due to mechanical stress, hormonal changes and in order
to maintain the bone mineral homeostasis. Bone remodeling displays three distinct
stages of skeletal growth in humans(2). During childhood bone remodeling leads to
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skeletal growth that reaches homeostasis at adulthood and with increased age leads to
a net loss of bone. Bone itself consists of an extracellular mineralized matrix, collagen
and cells. Bone remodeling is modulated by two important cell populations, osteoclasts
and osteoblasts(3). Osteoclasts are large, multinucleate cells that have abundant Golgi
complexes and lysosomal enzymes. They are responsible for bone resorption on the
surface of cells through the creation of resorption pits (also known as basic multicellular
units, or BMUs). Osteoclasts resorb bone through the processes of acidification and
proteolysis of the mineralized matrix. The other cell type, osteoblasts, are responsible
for the formation of new bone matrix in the resorption pits created by osteoclasts.
Osteoblasts cell are derived from multipotent mesenchymal stem cells which have the
potential to differentiate into several cell types including adipocytes, fibroblasts and
osteoblasts. Collagen I, the main structural protein within bone, is one of the first
proteins synthesized by osteoblasts during bone formation, followed by several nonstructural proteins. Osteoblasts complete bone formation by the mineralization of the
matrix of the bone. About 15% of mature osteoblasts are eventually embedded into the
bone matrix, some of which progress in differentiation to become osteocytes.
Osteocytes are cells within the bone that are responsible for mechano-transduction, and
modulate the activity of osteoblasts and osteoclasts. The two main types of bone found
within the skeleton are known as cortical and trabecular bone. Cortical bone supports
the body, protects the organs and is very dense. Cortical bone forms the outer shell of
bone and makes up the majority of weight in the human skeleton. Trabecular bone, also
known as spongy bone, has a high surface area and contains red bone marrow. Its
large surface area facilitates metabolic activity and production of blood cells.
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Most major bone related diseases, such as osteoporosis and Paget's disease,
occur when there is an imbalance in bone homeostasis due to different rates of bone
formation and resorption. Osteoporosis, an age related disease, leads to a lowered
bone mineral density that causes an increased risk of bone fracture. Fractures due to
osteoporosis usually occur within the hip, ribs, vertebrae and wrist and can often leave
the patient bed ridden. Diagnosing osteoporosis can be very difficult because those
affected by the disease are largely symptom free until a bone fracture occurs.
Osteoporosis predominantly affects women, with roughly 1 in 4 women over the age of
50 affected by the disease while only about 1 in 8 men over the age of 50 develop
osteoporosis. There are several causes suspected for the dramatic breakdown of bone
homeostasis including impaired osteoblast function, estrogen deficiency, poor vitamin D
metabolism, and other conditions including cancer, chronic renal failure and poor
nutrition. Glucocoricoid medications, drugs that are used for the treatment of arthritis
and other health issues, can weaken bones and lead to osteoporosis. Osteoblast
function becomes impaired during aging because of lowered proliferation rates, a
shorter functional lifespan, and increased adipocyte formation(4). The overall cause of
which is currently unknown but leads to weakened bone microarchitecture. One of the
most readily identifiable factors modulating osteoporosis in women is the loss of
estrogen, due to the effects of menopause. Menopause is the primary reason that
osteoporosis occurs at much higher rates in women than men. This can cause
osteoclasts, the cells responsible for bone resorption, to be more active and have a
longer lifespan(5). Estrogen deficiency is also known to increase the activation of BMUs
leading to higher rates of bone resorption, and a reduction in osteoclast apoptosis while
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at the same time increasing osteoblast apoptosis. These factors lead to high rates of
bone resorption that osteoblasts are not able to compensate for with increased age.
There are several FDA approved medications for treatment of osteoporosis that combat
the disease in different ways that include inhibiting osteoclasts, mimicking estrogen
activity and stimulating new bone formation.
Bisphosphonates are a class of drugs that are prescribed for treatment of bone
diseases such as Paget’s disease, hypercalcemia of malignancy and osteoporosis as
they are known to prevent the loss of bone mass. They are named after the two
phosphonate (PO3) groups that are bound to a carbon in their molecular structure.
Bisphosphonates have preferential binding to calcium due to the phosphonate groups in
their structure. Since bone has a high concentration of calcium, high levels of
bisphosphonates accumulate within the bone. When the osteoclasts break down bone
they absorb high quantities of the bisphosphonate. The drug then works by inhibiting
osteoclasts through apoptosis without affecting the mineralization of new bone(6). This
leads to a reduction of active osteoclasts cells which then slows the rate of bone
breakdown. Bisphosphonates can inhibit the resorption of bone caused by other agents
such as vitamin D deficiency, retinoids and calcitrol(7). Bisphosphonate treatment can
be more effective in preventing fractures when vitamin D is given in combination. Other
drugs that are prescribed that are effective in preventing bone loss and fractures,
include Teriparatide and Denosumab, with treatment usually proscribed by balancing
the benefits versus potential harm and cost of the drugs(8). Bisphosphonates typically
have a safe drug profile as they are known to be remarkably selective for their target.
There are some mild side effects such as rash, muscle and joint pain and inflammation
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of the eye. However this class of drugs is also known to be potentially toxic to the
kidney in larger doses, and is associated with a low frequency of osteonecrosis.
Bisphosphonate-associated osteonecrosis can cause the death of bone tissue within
the jaw. Currently there are about 11 different bisphosphonates used for clinical
treatment. Alendronate, known commercially as Fosamax, was one of the first
bisphosphonates developed and prescribed to treat osteoporosis and is still currently in
use(9). Alendronate is not only prescribed for postmenopausal osteoporosis but also for
glucocorticoids-induced osteoporosis and male osteoporosis(10).
Unlike humans, female mice do not undergo menopause, although they do
become infertile at around 11 to 16 months of age. The OVX mouse serves as a model
for accelerated bone loss of trabecular and cortical bone because it mimics the effects
of menopause from estrogen deficiency(11). The OVX mouse loses bone via estrogen
deprivation due to surgical removal of the ovaries(12,13). This makes the OVX mouse
an effective model for mimicking osteoporosis in humans due to menopause. The rate
of normal age-related bone loss has been shown to be well defined and consistent
within a number of inbred mouse strains which makes it possible to distinguish between
bone loss due to normal aging and bone loss due to estrogen deficiency(14). C57BL/6J
mice normally start losing trabecular bone as early as 6 weeks of age, and this
continues up until 24 months of age, while cortical bone mass peaks at around 6
months of age before it starts to decline(2). The ovariectomy surgery is known to have a
strong effect on both the trabecular and cortical bone health of the C57Bl/6J mouse(12).
MicroCT, or x-ray imaging in 3D at a high resolution, can be used to evaluate the
micro-architecture of both cortical and trabecular bone. CT scans can be performed in
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vivo at a low resolution or ex vivo using collected tissues at a high resolution resulting in
a more detailed and precise quantification of bone metrics. CT scans are one of the
more effective ways of diagnosing osteoporosis because it can be used to determine
various bone health metrics for both cortical and trabecular bone non-invasively. These
metrics include, but are not limited to, bone volume versus tissue volume, trabecular
separation and cortical thickness.
Gene expression analysis is an important tool in biology that is typically
performed on homogenates of cells(15). Gene expression is usually measured by
performing techniques such as quantitative PCR, which has high reproducibility and a
wide dynamic range. QPCR, or real-time PCR, is used to amplify and quantify specific
DNA targets. One potential problem when using a general homogenate of cells for gene
expression experiments is that one cannot distinguish the distribution of targeted
transcripts amongst the cell population. It is possible for a detected transcript in a
homogenized cell preparation to be evenly distributed within the cells or highly
concentrated within a small percentage of the overall cell population. This would mean
that the average expression levels detected would not necessarily reflect a typical
individual cell in the population. Single cell gene expression allows for the analysis of
specific cell types within a population(16,17). Single cell analysis is a growing area of
transcriptomic research with the potential to uncover new insights within proteomic,
transcriptional and metabolic functions of individual cells(18). Bengtsson et al.(19)
previously reported that mammalian cell populations have a lognormal expression
pattern. This means that when a cell population is lognormally distributed the average
expression level won’t reflect the expression levels of a typical cell in the population
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because the average expression is potentially based upon a small population of cells
with high transcription levels. Using whole homogenates for gene expression analysis
also ignores the individual contribution of different cell types. Recent research has
identified functionally distinct sub-populations within the osteoblast lineage, further
showing the importance of deriving single cells for expression analysis (20). Fluorescent
activated cell sorting (FACS) is a methodology for sorting cells based on the light
scattering of fluorescently labeled cells. FACS can be used as an effective single cell
sorting technique(21). This is accomplished by labeling proteins with a fluorophoreconjugated antibody that is only found within the desired cell population(14, 22). Single
cell analysis can use cells isolated directly from the source, which avoids potential
problems of using cells grown in vitro that may include potential differences in cell
behavior, specific location and physiological state of the cells(23).

Summary:
The human skeleton is a complex organ incorporating functions that include
blood cell production, supporting the body, calcium storage and endocrine regulation.
Osteoporosis is a serious age-related disease that affects a large population, with an
estimated 2 million fractures a year, and whose health effects have an annual impact of
around $17 billion a year in the United States(24,25). Osteoporosis causes low bone
mineral density and weakened bone architecture, and leads to an increased risk of bone
fractures that at a later ages leads to high mortality rates. In recent years, there have
been several breakthroughs in treating age-related bone disorders such as
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osteoporosis. This progress has been in part accomplished with the creation of
successful animal models that mimic age-related bone loss. A well-accepted animal
model of bone loss is the ovariectomized (OVX) mouse. Currently, many studies
examining bone and the mechanisms of bone loss use cell culture models, or employ
total bone cell homogenates(26,27). This method of study is often used because of the
difficulty of studying bone cells due to the fact that they are usually encased within an
ossified matrix. Using cell cultures is not ideal because it is not well understood how
osteoblasts transcriptionally vary from one type of bone to another(28). It can also be
argued that this approach is suboptimal with regards to appreciating the potential
importance of physiological or genetic changes in key cell types within the bone. The
Melov laboratory has developed a methodology for isolating osteoblasts (the cell type
responsible for bone formation) from intact bone(16). Such an approach allows the gene
expression of the isolated single cells to be studied one at a time. Single cell analysis
does not assume that individual cells within a population have the same gene
expression profile, and has powerful advantages over alternative methods that require
homogenizing all cells together (including different cell types).
This study analyses the gene expression profile of osteoblasts obtained from
bone from the OVX mouse model, with and without bisphosphonate treatment and then
identifying the gene expression signatures. Using the established technique,
osteoblasts cells were isolated from digested bone, stained with osteoblast markers
(CD31-/CD45-/AP+), and then collected using FACS. The isolated osteoblasts were
then assayed using qPCR for a set of 96 bone specific genes found within osteoblast
populations. This set of specific genes was refined through several control qPCR runs
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of osteoblasts obtained from C57/BL6J mice. These optimizing qPCR runs were used in
order to eliminate any genes that showed no gene expression in the control osteoblasts.
We supplemented new genes using current literature in the field of bone and osteoblast
research(29-31). These genes included, but were not limited to, sclerostin, an indirect
inhibitor of bone formation, AEbp1, a gene that plays a role in adipogenesis and has
been found in osteoblasts, and Sox2.
This study will provide the first single cell osteoblast transcriptional profile derived
in vivo from the OVX mouse model. This paradigm is used to assess the in vivo skeletal
phenotypes and subsequently relate them to the gene expression changes in freshly
isolated cells from the bones of treated versus non treated animals. This study will also
show the effects of bisphosphonate (Alendronate) treatment within the transcription
profiles of single cells during bone loss due to estrogen loss.

Materials and Methods
Animal Models and Treatment
The mice used in this study were obtained as a single cohort from Charles River
Laboratories. The mice had OVX or SHAM surgeries performed on them at 2 months of
age by the vendor, and after sufficient recovery time, the mice were shipped to our
facility. On arrival the mice were tattooed with a number (1-40) on their tail to aid in
identification. The mice were monitored for their health status throughout the study, and
weighed every week for a 16-week period. The weights of the individual mice were used
to determine the amount of Alendronate administered, and to record the expected
weight gain due to estrogen deficiency. Mice that were on bisphosphonate treatment
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were given a weekly I.P. injection of 100 µg/kg of Sodium Alendronate (Sigma Aldrich).
After 16 weeks of treatment, the mice were euthanized and tissues were collected for
analysis. During the euthanasia, all of the mice were visually inspected for the success
of the OVX or sham surgery. This was done by looking for the characteristic atrophy
normally found within the uterine horns of OVX mice. All animal procedures conformed
to Buck Institute IACUC guidelines and AAALAC standard operating procedures

MicroCT Analysis
All of the mice were scanned by µCT in vivo at a 35 µm resolution at arrival and a
week before they were euthanized. When euthanized, at the end of their treatment,
tissues were harvested from the entire cohort of mice in order to preform ex vivo scans.
The lumbar of the spine and half of the right femurs from each treatment group were
collected and preserved in 10% neutral buffered formalin. Both of these tissues were
scanned at a 9µm resolution, which allowed for more detailed measurements than that
of the in vivo (35µm) scans. The raw CT data was further processed in order to create a
3D volume for analysis with Nrecon v1.6 (Bucker, Inc.) using consistent dynamic range
values (minimum value: -0.002, maximum value: 0.135) in order to minimize the
background noise, ensure detection, and obtain consistent values between each
sample. Analysis of the CT data for bone metrics was quantified using image analysis
software CtAn v1.13 (Bruker Inc.). The femurs were evaluated for cortical bone at the
midshaft and trabecular bone in the growth plate. The midshaft analysis was performed
on a 2mm section of femur midsection. The growth plate analysis was performed on a
900 µm region of trabecular bone starting at 600 µm distal from a fixed anatomical
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landmark at the start of the growth plate. The spines were evaluated for trabecular bone
within the 1st lumbar vertebra. Cortical bone was evaluated using global thresh-holding
values of (low) 85 to (high) 255 grey scale values. All of the trabecular bone was
thresholded using grey scale values of (low) 60 and (high) 120 in order to avoid
detecting more dense cortical bone, and only analyze trabecular bone. Cortical and
trabecular bone were quantified using the 2D and 3D analysis packages of CtAn,
respectively. The trabecular bone health metrics that were examined include bone
volume versus tissue volume, trabecular number (Tr. number), and trabecular
separation (Tr. separation). Bone volume versus tissue volume simply measures the
total volume of bone versus the total volume of empty space/tissue of the VOI. Tr.
number, also known as the structure linear density, enumerates the number of
traversals across a solid structure made on a linear path through the trabecular bone
region. Tr. separation is the thickness of the empty spaces within the VOI. For cortical
bone analysis we looked at bone volume versus tissue volume, crossectional thickness,
and area. BV/TV operates under the same principle as defined for trabecular bone
analysis. Crossectional thickness and area, look at the thickness and the area of the
midshaft donut that makes up the volume of interest.

Single Cell Collection and Analysis
After the mice were euthanized, the isolated femurs were cleaned, and
epiphyses from both ends were removed, and the resultant diaphysis was subsequently
flushed with PBS in order to remove the majority of marrow and hematopoietic cells
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from the femur. Once the femurs had been cleaned they were then preserved in a
modified media and stored at -80° C as described in Flynn et al(16). In order to obtain
the single cell cortical osteoblasts, femurs underwent a series of enzymatic digestions
using 0.2% collagenase in a phosphate buffered solution. The collagenase bone
digestions occurred within a shaker kept at 37° C for a 30 minute period. Before the
second collagenase digestion, the femur was finely crushed in order to increase the
yield of osteoblast lineage cells by dispersing the bone cells. After the collagenase
digestions, the disrupted bone was spun down and the supernatant was removed. The
supernatant was then spun down in order to obtain the pellet of cells to be sorted. A
mild fixative was added to the cell pellet in order to better preserve RNA integrity. At this
stage of single cell isolation there was a heterogeneous cell population from the bone
matrix which was then stained using antibodies against specific cellular markers
(CD31-/CD45-/AP+). The CD31 marker is found in osteoclast cells and CD45 is found in
hematopoietic cells, while alkaline phosphatase is specific for the osteoblast lineage as
it is involved in laying down bone. Using florescent-activated cell sorting (FACS) we
selected for cells that were detected with negative CD31, CD45 and positive for AP
florescence. A minimum of four individual biological replicates were used per treatment
group for FACS and to isolate the individual cells. The osteoblast single cells were
collected via micro-pipet and transferred to individual tubes for gene expression
analysis. At least 110 individual osteoblast cells were collected for each treatment group
with an overall total of 480 individual osteoblast lineage cells collected. These
processed cells were then frozen at -80°C until qPCR gene expression analysis.
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Single Cell Gene Expression
The isolated individual osteoblasts cells were assayed using a single cell qPCR
procedure. The procedure uses direct reverse transcription and specific target
amplification prior to microfluidic qPCR. The individual cells were isolated using a micromanipulator and then placed in PCR tubes with a small volume of 1-2 µl that were then
immediately frozen on dry ice and then stored at -80° C. When the qPCR was ready to
be performed the cells were thawed on ice. Then the cells were pre-amplified using
specific target amplification of relevant genes containing all 96 assay primers sets for 18
cycles using the Cell-Direct RT-qPCR kit (Invitrogen). The single cell pre-amplified
product was then diluted 1:5 in a DNA suspension buffer and then assayed using
Fluidigm’s 96.96 nanofluidic qPCR on a Biomark HD system. Biotium’s EvaGreen DNA
binding dye was used to detect amplified product according to Fluidigm’s advanced
development protocol #30(23). The exported qPCR data files were then normalized
using Singular R analysis package (v1, Fluidigm) in order to obtain Log2Expression
values for each reaction.

Statistical analysis
All of the statistical comparisons for this study were tested using a nonparametric randomization test using the statistical software R (16). Treatment groups
were compared and the null was rejected if p<0.05. These statistical tests were
performed in order to avoid the assumption of a normal distribution within our samples,
especially for the single cell gene expression analysis. Pairwise comparisons were
made using permutation test and multiple testing correction was applied to identify
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differential gene expression (Benjamini-Hochberg. 5% FDR). The CT statistical analysis
was performed by comparing the statistical differences between the specific treatment
groups including: SHAM versus OVX, SHAM versus OVX+ALD, SHAM versus
SHAM+ALD and OVX versus OVX+ALD. ANOVA P-value testing was used to
determine the statistical differences in gene expression for each treatment group.

Results
In order to derive a source for our osteoblast lineage cells we obtained a cohort
of 40, 2-month old C57BL/6J mice. Half of the mice had OVX surgery performed while
the other half had a SHAM surgery. Once at our facility the mice were divided into four
groups of 10, with one group from each surgical treatment receiving Alendronate (100
µg/kg) treatment once every week via I.P. injection. This resulted in 4 treatment groups:
OVX, OVX+ALD, SHAM and SHAM+ALD. After a 16 week period, the mice were
euthanized and tissues were collected for osteoblast cell collection for qPCR and CT
scans (Figure 1).

Estrogen Depleted Bone Loss is attenuated or reversed by Alendronate
The weights of the mice were closely monitored in order to determine the
success or failure of the OVX surgery(Figure 2), as occasionally the surgical procedure
is not successful. The OVX estrogen deficient mice showed the expected weight gain at
approximately 59 to 66 days post-surgery when compared to the SHAM controls. This
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elevated weight gain was maintained for the full 16 weeks in the OVX group. However
by the end of the 16 week treatment, the OVX+ALD weights were not significantly
different from the SHAM treatments. There was no statistically significant difference in
weights between the SHAM and SHAM+ALD treatment groups throughout the study.
After the mice were euthanized for tissue collection their uterine horns were visually
inspected for atrophy (Figure 2). All of the OVX treatment mice showed clear atrophy in
their uterine horns, as expected, while the SHAM mice had uterine horns that had
proper blood flow and normal appearance, confirming that the OVX procedure was
successful in the OVX mice used in this study.
In order to show that estrogen deficiency results in bone loss in mice and that
treatment with Alendronate can modulate/attenuate these effects, and even lead to
greater bone mass, spines and femurs were collected for 3D visualization via CT scans.
The first lumber vertebrae (Lumbar 1) of the spine was scanned at a high resolution and
subvolumed in order to investigate the bone health metrics of the trabecular bone for
each treatment group of mice (n = 9)(Figure 3). The OVX mice showed a significant
decrease in Tr. number, along with a significant increase in Tr. separation when
compared to the SHAM mice. This indicates that there is ongoing bone loss in the OVX
mice as there is not only a clear reduction in bone mass but an increase in the empty
spaces within the trabecular bone network. Treatment with Alendronate in the OVX
mice was able to reverse the increase in Tr. separation, and lead to higher BV/TV and
Tr. number values. SHAM+ALD treatment mice also showed improved bone metrics but
only showed enhanced metrics in Tr. separation when compared to the OVX+ALD mice.

23

The right femurs for 5 mice per treatment group were collected for micro CT
while the rest of the femurs were collected for single cell osteoblast collection. Analysis
of the bone loss found in the femurs was important to characterize since the osteoblasts
cells were derived from the femur. The femurs were scanned at a high resolution (9µm)
and subvolumed in order to investigate the cortical bone of the midshaft, and the
trabecular bone of the femoral growth plate (Figure 4). The cortical midshaft (mid-point
+/- 1mm) of the femur showed a significant reduction in mean crossectional area and
thickness of the femur in OVX mice versus the SHAM control mice. There was no
difference in the overall bone volume in the OVX mice when compared to the SHAM
mice. OVX+ALD did not seem to have a significant impact on the changes in cortical
thickness and cortical area observed in the OVX but there was a trend towards an
improvement both metrics, almost restoring them to the levels found in the SHAM
controls. As expected the SHAM+ALD had the healthiest bone metric values out of all
the treatment groups. These results indicate that there is a likely thinning of the cortical
bone in the midshaft of the femur that is to be expected from the OVX surgery. This
showed that the targeted source of osteoblasts cells, the cortical midshaft of the femur,
was clearly undergoing bone loss.
The femurs were also examined for trabecular bone loss in the femoral growth
plate. The BV/TV and Tr. number were significantly higher in both of the ALD treatment
groups. The Tr. separation was also significantly lower in both the ALD treatment
groups when compared to their OVX and SHAM counterparts. There was a significant
change in Tr. Separation and Tr. number in the OVX versus SHAM mice along with a
small, but significant, difference in BV/TV. This suggests that there is a change in the

24

femoral bone architecture due to the estrogen deficiency from OVX surgery. Overall the
results from the bone analysis of both the femur and the spine demonstrated that the
Alendronate treatment is either able to slow or prevent the bone loss that occurs due to
estrogen deficiency in the mice, consistent with prior literature.

Single cell gene expression of isolated osteoblast cells
Once it was established that both the ovariectomy procedure and the
pharmacological intervention were affecting bone loss as expected we moved on to
isolating the single cell osteoblasts from the femurs of the mice using a previously
established technique developed by the Melov lab. This method involved using multiple
collagenase digestions of the femur in order to obtain the cell population. The cells were
then labeled using fluorescent antibodies for CD31, CD45 and Alkaline Posphatase
(AP). Once the cells were properly labeled, FACS was used to obtain a pure population
of osteoblast cells. At least 4 biological replicates were used for each treatment group
with approximately ~120 single cells isolated per group. The collected osteoblast cells
were then prepared for single cell gene expression analysis using specific target
amplification for 96 gene expression assays (Figure 5). The amplified material was then
run on nanofludic qPCR arrays to generate the single cell expression profiles. The
qPCR amplification data was analyzed using Fludigm’s single cell gene expression
package in the R statistical programming environment.
The resulting log2 expression values of each gene were used for statistical
analysis, including the generation of a heat map of the gene expression values for each
osteoblast (Figure 6). The genes in the heat map were organized using hierarchical
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clustering in order to identify groupings of genes that had a similar expression pattern
among the four treatment groups. In order to determine whether or not one specific
animal affected any of the expression results we labeled each cell with the animal ID.
By doing this we were able to determine that none of the osteoblasts derived from a
specific animal drove any of the osteoblast expression patterns that were found in the
heat map. Along the side of the heat map the individual osteoblast cells were labeled
with their specific treatment group and clustered in order to determine if any profiles
appeared. In order to effectively identify if there were any novel subsets of osteoblast
gene expression principal component analysis was performed on the single cell gene
expression data (Figure 7). The PCA analysis was used to reveal if either estrogen
depletion or Alendronate treatment affected the overall gene expression profile. The
PCA analysis revealed that there was a group of osteoblast cells that did segregate
based on O, OA and SA treatment. However, there were no clusters of cells that
segregated based on an individual treatment group. This lack of segregation due to
treatment is not necessarily surprising as it is likely due to the fact that all of the
osteoblasts cells were derived from a purified population assayed for bone specific
markers and bone associated genes.
In order to determine if there were significant changes in gene expression within
the different single cell osteoblast treatment groups, we assessed the log2 expression
values of each gene using ANOVA P-value testing. These results were then graphed
using violin plots of the gene expression data for each individual gene, with expression
separated based on treatment group (Figure 8). Every extension of the violin plot, on
the y axis, represents the expression level of the specific gene, with the cell count

26

indicated by how wide the violin plot was at different log2 expression values. The violin
plots of the genes were organized with genes that had greatest differential expression
between treatment groups located at the top of the figure and those with the lowest
differential gene expression at the bottom. The violin plots showed that there were a
number of genes with differential gene expression within the osteoblast treatment
groups.
The largest differential gene expression profiles were found in genes that had
higher levels of expression in cells located in the OA, S and SA treatment groups. This
indicates that estrogen depletion causes gene alterations that seem to be reversible
with Alendronate treatment in many of our selected genes. The functions of these genes
ranged from cell cycle control, ossification, cell differentiation, osteoblast cell fate,
developmental pathways, to mitochondrial associated genes. The other common
expression profile within the genes had higher expression values in cells in the O, OA
and SA treatment groups. Many of these genes are mitochondrial related and involved
in electron transport, NADH dehydrogenase and even cellular response to oxidative
stress. This grouping of genes indicates that there might be a subpopulation of genes in
osteoblasts that are more highly expressed due to both estrogen deficiency and
Alendronate treatment. The two other notable expression patterns found within violin
plots had genes with higher expression values in the SHAM treatment groups, and in
both Alendronate treatment groups. The genes with high expression in only the SHAM
treatments likely represent genes that are lost due to estrogen deficiency regardless of
Alendronate treatment. The function of these genes included osteoblast differentiation,
protein transport and mitochondrial related actions. In the same regard the genes with
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higher expression values found only in Alendronate treatment groups were likely due to
the administration of the drug. Both BMAL1 and CYC1 had higher gene expression
values due to Alendronate treatment. The only gene that showed higher expression
values, though only slightly, in the OVX treated cells was NOTCH3, which is known to
regulate cell fate and impair osteoblast differentiation.

Discussion
Both the ovariectomy mouse model and bisphosphonate treatment have well
defined impacts on bone loss. However, these treatments’ in vivo effects on osteoblast
lineage cells are poorly defined. In order to gain a better understanding of how these
treatments work within the targeted tissue, we applied a new single cell method to
isolate and profile the gene expression of individual osteoblast cells. This study
combines both ovariectomized mice and Alendronate treatment to better understand
their effects on osteoblasts and osteoblast signaling.
Once the efficacy of the surgery was determined, via tracking of the expected
weight gain and visual inspection of atrophy within the uterine horns of the mice, we
wanted to confirm the expected bone phenotypes. High-resolution microCT scans of
both the spine and femur were used to confirm that estrogen deficiency caused bone
loss and that Alendronate treatment could lead to improved bone health. The CT data
showed that estrogen deficiency had a significantly negative impact on both trabecular
and cortical bone health metrics and that Alendronate treatment was able to slow or
reverse much of the bone loss seen in the OVX mice and even improved bone health
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metrics in the SHAM control mice. Alendronate treatment was only able to lead to
significantly increased cortical bone health in the SHAM mice but a clear trend towards
increased bone health was seen in the OVX mice. These microCT results allowed us to
confirm that the each treatment group altered bone health metrics as expected.
With the osteoblast lineage cells successfully isolated, qPCR was performed for
96 genes in order to generate gene expression profiles for all of the collected cells. The
overall expression of mRNA within these cells was low but measurable when compared
to other cell types(23). The principal component analysis of the expression data showed
that neither the estrogen depletion nor the Alendronate treated cells seemed to
segregate based solely on individual treatment group. However when the expression
levels for each gene were analyzed many differentially expressed genes were identified.
The most common expression profile found within our selected genes had higher levels
of expression in the OA, S and SA treatment cells. These genes had significantly lower
expression levels in the OVX treated cells and saw restored expression levels in OVX
mice that were treated with Alendronate. These results suggest that these genes are
responsible for modulating bone loss in this model. This conclusion seems likely as
many of the genes found in this expression profile are known to be responsible for bone
formation and osteoblast development, such as Axl4, BMP7, IGF1 and Osterix. These
expression profiles may account for the poor bone health metrics found in the OVX mice
and the improved bone health observed in the OVX+ALD treatment mice. We examined
the profiles of genes within this expression profile for any interesting expression
changes that could validate the biological changes seen in the bones of the mice used
in this study. One gene that stood out was IGF1 which is known to be a key gene in the
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signaling pathway of bone development and partially responsible for osteoblast
differentiation. For these reasons IGF1has a vital role in terms of the development and
function of the skeletal system. This indicates that estrogen deficiency, in part, causes
bone loss due to low levels of IGF1 expression and that Alendronate is able to reverse
the change in IGF1 expression. Interestingly IFG1-receptor had high expression levels
within all of treatment groups, with the lowest levels of expression found in the SHAM
treatment cells. This indicates that the levels of IGF1 expression are a key limiting factor
in the IGF1 bone formation pathway rather than the amount IGF1-recptor found within
the osteoblast cells. CCRN4L, or nocturnin, was another interesting gene that showed
high expression levels in OA, S, and SA treated osteoblast cells. This result was
unexpected as several studies have found that nocturnin suppresses the I1 anabolic
pathway and lowers IGF1 expression. However, nocturnin may have some other
beneficial effects on bone health, even with its negative effects on IGF1, as it was highly
expressed in OA, S and SA treatment groups, the treatment groups that had best bone
health metrics.
The other major expression profile we discovered in our qPCR data had genes
with higher expression in all treatment groups except for the SHAM treatment cells.
Genes within this expression profile had several different functions but there were many
genes, such as ND3, CYTB and ND4L, which had mitochondrial related functions. The
increased expression of mitochondrial genes could indicate higher levels of
mitochondria, and an increase in energy production in the osteoblast cells which would
be expected to improve the rate of bone formation. This would help to explain why the
SHAM+ALD mice had improved bone health metrics when compared to the SHAM
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mice. Interestingly, these genes were also more highly expressed in the OVX treatment
cells but it does not seem like their increased expression is sufficient for bone
development.
There were several genes that showed higher expression levels in only the
SHAM treatment groups. These genes appear to be unaffected by Alendronate
treatment in our osteoblast cells. The genes that had higher expression only in the
SHAM osteoblasts have functions that include bone formation, osteoblast differentiation
and regulation of calcium ions. COL1A1, Osteopontin, and SORT1 are examples of
these genes that are also known to have positive effects on bone health. COL1A1, the
gene for Collagen Type I Alpha 1, is one of the major structural components of bone
that is laid down by osteoblasts. This makes COL1A1 a interesting target to investigate
further in order to help combat bone loss due to estrogen deficiency as Alendronate
treatment was not able to reverse its loss in osteoblasts. Notch3 was one of the few
genes that was more highly expressed in only the OVX treatment cells. Notch3 is a
receptor for membrane bound ligands that has been found in osteoclasts and
importantly has been discovered to arrest osteoblast differentiation. Genes like Notch3
and COL1A1, whose expression seems to be unaffected by bisphosphonate treatment,
offer up new potential targets for the treatment of osteoporosis and other bone related
disease, either in conjunction or separate from Alendronate treatment.
This study measured single cell gene expression of in vivo derived osteoblast
cells. We were able to identify a suite of differentially expressed genes due to both
estrogen

depletion

and

Alendronate

treatment,

from

an

otherwise

homogenous gene expression profile within the osteoblast cells.
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relatively

This potential to

analyze gene expression changes at the single cell level allows for the testing of other
osteoporosis treatments with unknown efficacy in the OVX model along with the ability
to analyze single cells within other future model systems.
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Figure 1. Flowchart of Study. Outline of the steps involved in this study. Briefly, 40
C57BL/6 mice were obtained with an ovariectomy surgery performed on half of the
cohort and a SHAM surgical control preformed on the other half. The mice were kept for
16 weeks with half of each surgical group on Alendronate treatment. After the 16 week
period the mice were euthanized for collection. Femurs were then microCT scanned to
evaluate the bone microarchitecture or used for osteoblast isolation. QPCR was then
preformed on all obtained osteoblasts.
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Figure 2. Efficacy of OVX & SHAM Surgery. The weights of the mice were tracked
weekly at the start of the Alendronate treatment in order to observe the success of the
OVX surgery. As expected, the mice with the OVX surgery gained more weight versus
the SHAM controls at around 8 weeks post-surgery. The uterine horns of each mouse
were examined after euthanasia in order to confirm atrophy of the uterine horns. The
SHAM uterine horns had a normal appearance while the OVX uterine horns showed
atrophy, as indicated by the blue arrows.
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Figure 3. Ex vivo CT analysis of Spine 16 weeks post-surgery. Lumbar 1 of all the mice
were scanned by µCT, ex vivo, at a high resolution (9 um) in order to analyze the effects
of estrogen depletion and Alendronate treatment on the trabecular bone health of the
mice. The bone health metrics that were used for analysis were BV/TV, Tr. separation
and Tr. number (n= 9 per group, p<0.05). The estrogen depleted OVX mice showed a
significant reduction in BV/TV and Tr. Number and increased Tr. separation. Treatment
with alendronate reversed these changes in the trabecular bone and lead to improved
trabecular bone health in the SHAM control mice. Below the bar graphs are images of
3D models of the volume of interested analyzed that are representative for each
treatment group in the study.
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Figure 4. Ex vivo CT analysis of femurs 16 week post-surgery. In order to analyze bone
loss from the area in which the osteoblast cells were derived femurs (n= 5 per group,
p<0.05) were collected for each treatment group. The femurs were scanned by µCT, ex
vivo, at a high resolution (9um). The cortical bone, the midshaft of the bone, and the
trabecular bone, a section of the growth plate, were analyzed using standard bone
metrics. The mean crossectional area and thickness of the femur midshaft were
significantly reduced in the OVX treatment versus the SHAM control while the overall
bone volume showed no significant difference. The trabecular BV/TV, and Tr. Number
were both significantly higher, along with a significant decrease in Tr. Separation, in
both of the alendronate treatment groups. In the trabecular bone there is significant
difference in Tr. separation between OVX and SHAM treatment mice. There is also a
small but still significant decrease in BV/TV and Tr. number in the OVX versus SHAM
mice. This indicates that there is still a potential change in the bone architecture of the
femur due to estrogen deficiency.
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Genes used for qPCR Assays
AEBP1

Axl4

BGLAP

BGN

BMAL1

BMP6

BMP7

BTG2

CCNA2

CCNB1

CCR6

CCRN4L

CD105

CD5

CD79A

CD79B

CDK2

CDKN1B

CD31

CD44

CD45

CHRNA1

CKIP1

COL1A1

COL1A2

COX1

COX2

CRYAB

CTNNB1

CXCL12

CXCR4

CYC1

CYP51

CYTB

EFNB2

EPHB4

FGF21

FOXO1

FOXO3

HLA_DR

ID4

IGF1

IGFBP2

IGFR1

KERA

LEPRINR

LHX2

LIQCR10

LRP130

MGP

MMP13

MMP14

MSX2

ND2

ND3

ND4

ND4L

ND5

ND6

NDUFB2

NDUFS4

NDUFV1

NOTCH3

Notch4

OMD

Osteopontin

Osterix

Pax1

PER1

PER2

PGC1A

PGC1B

Pleiotropin

POSTN

PPARALPHA

RAB15

REV_ERBA

Runx2

Sclerostin

SMAD5

SMURF1

SORT1

SOST

SOX2

SOX9

SPROUTY1

SPROUTY2

TFAM

TNFSF11

TNMD

TRPM8

VCAN

WIF1

WISP1

WNT10B

WNT5A

Figure 5. Table of 96 genes used for qPCR gene expression assays. This table shows
all 96 bone and osteoblast related genes that were used for the qPCR assays of the
single cell isolated osteoblasts obtained in this study. The genes selected were mainly
bone specific and bone related genes along with some cell cycle and mitochondrial
related genes.
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Figure 6. Heat map of single cell osteoblast gene expression. The log2 expression
values for each cell are shown based on a global z scale score with red indicating a
high gene expression value and blue indicating a low expression value. The genes were
clustered in order to identify any expression profiles among the 4 treatment groups of
osteoblast cells. Along the side of each row of the heat map cells were labeled with their
treatment group and the animal ID from which they were originally derived. This was
done to determine if any of the expression patterns were due treatment group or the
individual mouse they were derived from.
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Figure 7. Principal Component Analysis of single cell gene expression data. The gene
expression profiles of the 480 isolated osteoblasts generated using 96 gene expression
assays were examined with Principal Component analysis. The PCA analysis indicates
that there are very little distinct profiles observed among the treatment groups. The one
unique subset that is found within the cell populations, located in the lower right
quadrant of the PCA score plot, shows cells clustering due to O, OA, and SA treatment.
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Figure 8. Violin Plots of the Log2 Gene Expression Levels for each Treatment group.
All expression data from the osteoblast qPCR runs was used to find the Log2
Expression levels for all 96 genes we examined in this study. The Log2 Expression
levels were than used to create violin plots for the expression values of all 96 genes for
each treatment group (S = SHAM, SA = SHAM + ALD, O = OVX, and OA = OVX +
ALD). Genes were organized due to differential expression among the four treatment
groups, with those having the greatest differential expression located at the top left of
the figure and genes with the lowest differential expression found at the bottom right
section of the figure.
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